开发基于化物的HDAC6选择性抑制剂,用于治疗NLRP3炎症相关疾病
Kairui Yue1, Simin Sun1, Zequn Yin2
1Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266071, China.
Journal of medicinal chemistry
|April 7, 2025
概括
研究人员通过添加原子开发出一种更有选择性的HDAC6抑制剂,即化合物9m. 这种新型抑制剂对治疗NLRP3炎症相关疾病具有较少副作用的前景.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 化物部分以前被确定为HDAC6抑制剂的结合组.
- 最初的基于化物的HDAC6抑制剂 (35m) 显示出有限的异型选择性.
- 提高HDAC6的选择性对于减少潜在的副作用至关重要.
研究的目的:
- 为了增强基于化的HDAC6抑制剂的异型选择性35m.
- 确定一种具有强效和选择性的HDAC6抑制剂,具有更好的安全性.
- 评估新型抑制剂在NLRP3炎症相关疾病中的治疗潜力.
主要方法:
- 进行了结构-活性关系 (SAR) 研究.
- 在左边的环上,在特定位置引入了原子.
- 实验室试验用于确定HDAC6抑制和异型选择性.
- 评估了药物动力学特性和安全性概况.
- 在体内疾病模型被用于评估治疗疗效.
主要成果:
- 化剂显著改善了基于化的抑制剂的HDAC6选择性.
- 化合物9m显示出高强度 (IC50 = 0.021μM) 和HDAC6.6的> 335倍选择性.
- 化合物9m表现出良好的药理动力学和改善的安全性.
- 9m有效抑制了NLRP3炎症酶激活.
- 在急性腹膜炎,炎症性肠病和牛皮的模型中观察到显著的症状缓解.
结论:
- 替代是设计选择性HDAC6抑制剂的有效策略.
- 化合物9m代表了一种有前途的化合物,用于治疗NLRP3炎症酶介导的炎症性疾病.
- 这项研究为针对炎症性疾病的向疗法的设计提供了宝贵的见解.
相关概念视频
02:26NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...